The retail investor market is dead for nnlx for the

New Post Public Reply Private Reply Replies (1) Message Board
nmbr1stckpckr
The retail investor market is dead for nnlx for the following reasons:

1. This is a pink sheet stock.
2. The stock is thinly traded.
3. The trend has been decline regardless of the good news.
4. The premium (difference between bid and ask) is huge.
5. It is not possible to purchase a big lot of shares at the ask without driving the premium even higher.
6. It takes extraordinarily long to get shares filled at the bid.

A thought occured to me just now after laying out the above list -- I`m not so sure that growing the sophisticated investor base (SIB) mentioned in post 194 (http://investorshangout.com/post/view?id=1930922) would necessarily drive up or stabilize the share price. The SIB may be willing to pay the premium, but unless they have very deep pockets, they will not be able to stand up to the manipulators. I am, however, confident that the SIB would be steadfast in holding onto their shares regardless of the decline in share price as long as the company continued to progress. I think the steady erosion in share price over the years on thinly traded shares is evidence of this.

A large part of the basher rhetoric has been that there is no interest in the stock even in spite of the recent spate of good news as evidenced by the absence of buying pressure. They question why the existing longs don't buy more while purposefully ignoring factors such as limited funds and comfort levels of exposure to the different types of investments that make up one`s portfolio. I suspect most of us fall into one or both of these camps. My list above addresses the obvious `what about new investors?` salvo that follows like clockwork.

But what about those, existing and new SIB, that do have funds to invest? Surely there must be some. Some here have claimed that they aren't buying any more shares until the Company becomes more transparent, in part or whole, about their activities. That's fine, but there must be others that are willing to invest based on their evaluation of the technology, the IP and the potential impact to the IVD market, especially after what's been made known of the N-Assay.

It's taken a while to get around to writing down the thought that occurred to me earlier, but here it is. We know that PIPES have been used in the past to fund general operations, make capital improvements, purchase equipment, etc., when there wasn't any revenue to speak of. The general feeling seems to be that the Company is not releasing financials because it's not yet strong enough yet to break the manipulators. Could it be that those currently part of and those new to the SIB are participating in PIPES presumably at some lower level than in the past to supplement revenues?

I can hear the bashers going bonkers with ecstasy over such a revelation if it were the case, but they would be wrong as usual. Think about it. They killed the demand in the retail market. They destroyed the share price. They made it extraordinarily difficult and expensive for new SIB to get their shares on the open market. They basically drove the SIB into the only option they have to get a lot of shares at or near the current share price without having to worry about causing and paying for volatility due to their large purchases; that option being to purchase directly from the Company. Sure it hurts the Company because the shares would be sold WAY undervalued, but not nearly as much as it would have hurt if the Company had to sell shares on the open market.

If PIPES did occur recently or are happening, it would help to explain the absence of buying interest on the open market. And it might also help explain the perceived snubbing by some investors currently holding stock and suffering mental anguish because all they focus on is the manipulated share price and not on what the Company has achieved and the potential to achieve so much more soon. Instead of blaming the manipulators, they blame the Company for not doing more to protect the share price. The Company has put out FANTASTIC news recently without anything but a negative reaction in the share price. Take a moment to consider this fact and if you still think being more transparent at this point will help the share price...well, sad day for you.

The Company is focused on the long game as they currently don't have the resources to deal with the manipulators. I am more confident than I have ever been that the Company will be wildly successful and that the share price will follow. Financials won't matterr so much if the Company gives out dividends. I'm just saying.



Nanologix Inc (NNLX) Stock Research Links

NNLX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Labcorp Lifts 2026 Guidance Amid Strong Q3 Performance

Updated Category News Views 80

Labcorp's Q3 Numbers Speak Loud and Clear Another quarter, another robust set of numbers for Labcorp (NYSE:LH). The company is strutting into the spotlight with third-quarter 2026 results that have investors nodding in approval. Revenue surged to $3.81 billion, marking a 6.9% increase from the prior year's $3.56 billion. And get this: adjusted EPS jumped 14.5%, clocking...

Continue Reading
SoftwareOne Triumphs in 2026 GitHub Partner Awards

Updated Category News Views 43

SoftwareOne Nabs Prestigious GitHub Honor Outta nowhere, SoftwareOne's been lashed onto the center stage, bagging GitHub's Global Channel Sales Partner of the Year for 2026. This ain't just another shiny trophy on the shelf; it's a solid nod to their grit and strategy. Now, if good old GitHub says you're their top dog, you're obviously doing something right. Not bad for a...

Continue Reading
AppLovin Faces Class Action: AI Growth Claims Under Fire

Updated Category News Views 14

AppLovin's AI Jackpot: A Busted Flush? This year's been a rollercoaster at AppLovin Corporation, and not the fun kind. Let me tell ya, investors bought into a dream—a self-sustaining, profit-churning machine based on AI advertising models. Unfortunately, reality came around like a bad penny, and suddenly, their 'virtuous cycle' feels more like a busted flush....

Continue Reading
HERVolution's HERV-K Antigens: A Cancer Breakthrough?

Updated Category News Views 0

Digging into HERVolution's Game-Changing Data Picture HERVolution in the spotlight, rolling out data that could shake up our approach to cancer immunotherapy. The big headline? HERV-K antigens might just be the whistle-blower we've been looking for to get the immune system off the bench and onto the field. How's that for a kick in the conventional wisdom of cancer...

Continue Reading
QFIN Faces Lawsuit Over Broken Promises and Revenue Plunge

Updated Category News Views 35

Unmasking the Hype: QFIN's Pledge and Performance Investors, gather 'round because QFIN's latest uproar ain't pretty. The folks over at Qfin Holdings have found themselves in hot water, facing a class action lawsuit for allegedly pulling the wool over investors' eyes. Between March and August 2026, they promised a rock-solid ship braving China’s regulatory storm. Turns...

Continue Reading
Lynk Pharmaceuticals' Zemprocitinib Shines in Phase III RA Trial

Updated Category News Views 112

A Deep Dive into Lynk Pharmaceuticals' Latest Revelation Lynk Pharmaceuticals just dropped a bombshell with their latest Phase III trial results for zemprocitinib. This selective JAK1 inhibitor seems to be bringing some serious game in the fight against moderate-to-severe rheumatoid arthritis (RA), especially for folks who haven't had much luck with biologics. The drug...

Continue Reading
Faith on Trial: La Luz del Mundo Faces Court Ruling

Updated Category News Views 21

A Legal Battle Over Religious Freedom When folks start talking about religion intertwining with law, things get real tricky, real quick. The La Luz del Mundo church is knee-deep in such a legal tussle. On October 28, 2026, the United States District Court for the Southern District of New York gave a nod to the prosecution, denying the church's pretrial motions. What we've...

Continue Reading
Corgi Insurance Eyes $100B Auto Market with New Launch

Updated Category News Views 194

Leaping Into a Booming Market Well, it looks like someone lit a fire under Corgi Insurance, and they're ready to chase bigger bones. They’ve just rolled out a product called Corgi Business Auto, signaling quite a bold move into the hefty, nearly $100 billion U.S. commercial auto insurance arena. Now, as an old hand at this game, my ears perk up whenever I see a player...

Continue Reading
Pave and Levels.fyi Unite: Revolutionize Pay Decisions

Updated Category News Views 0

Diving straight into the heart of it, here's a move in the business world that's all but marking its territory on the compensation landscape. Pave, already a big player in agentic compensation management, is shaking hands with Levels.fyi, a platform prized for its real-deal compensation data detailed down to the company, level, location, and skill. These folks are...

Continue Reading
Honeywell Aerospace Posts Solid Q3, Raises Guidance

Updated Category News Views 39

Honeywell Aerospace Surprises with Strong Third Quarter In a world where numbers are often as slippery as a greased pig, Honeywell Aerospace (NASDAQ:HONA) has managed to pin down a surprisingly robust third quarter. Let’s break it down: they’ve claimed sales of a cool $4.6 billion, reflecting a 2% bump both in reported and organic revenue from the previous year, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Pyxis Oncology Focuses on Breakthrough Therapy PYX-201

Updated Category News Views 205

Pyxis Oncology Redirects Focus to Leading Therapy PYX-201 Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage biotech firm, has announced a significant shift in its strategic direction by prioritizing its lead clinical program, PYX-201. This innovative antibody-drug conjugate (ADC) is engineered to target specific components within the tumor extracellular matrix, aiming...

Continue Reading
Ecovyst's Q3 Performance and Strategic Moves for Growth

Updated Category News Views 98

Ecovyst's Third Quarter Performance and Strategic Insights Ecovyst Inc. (NYSE: ECVT), a notable provider in the chemical industry, recently revealed its financial performance for the third quarter of 2025, showcasing significant progress in its operations and strategic decisions. The company specializes in the production of virgin sulfuric acid and regeneration services,...

Continue Reading
Consumer Interest Grows for Monthly AI Home Assistant Services

Updated Category News Views 447

Consumer Willingness to Invest in AI-Driven Home Solutions Recent research into consumer preferences reveals that a significant portion of the population is ready to embrace AI-assisted smart home technology. Parks Associates' compelling study finds that between 42% and 52% of consumers are inclined to subscribe to a monthly service for an AI smart home assistant that...

Continue Reading
Tuya Smart Introduces Hey Tuya: Revolutionizing Everyday AI Assistants

Updated Category News Views 186

Tuya Smart Unveils Hey Tuya: A Game-Changer in AI Technology In a notable advancement in AI technology, Tuya Smart (NYSE: TUYA) has introduced its innovative platform called Hey Tuya. This next-generation Super AI Life Assistant is set to redefine how individuals interact with artificial intelligence in their daily lives. The initiative represents a significant leap...

Continue Reading
Innovative Food Packaging Concept Redefines Convenience

Updated Category News Views 384

New Approach to Food and Beverage Packaging In an ever-evolving world where efficiency and convenience are paramount, an inventive solution has emerged. An inventor, motivated by the challenges of transporting, preparing, and storing food, has conceptualized an improved packaging design that promises to revolutionize these everyday tasks. Why This Invention Matters This...

Continue Reading